Once laud­ed for its clin­i­cal suc­cess, Roche casts off car­dio pro­gram in­clacum­ab for a mere $2M to Glob­al Blood Ther­a­peu­tics

Five years ago, Roche tout­ed a clin­i­cal suc­cess for one of its mid-stage car­dio pro­grams, re­port­ing the in­ves­ti­ga­tion­al med showed promise in re­duc­ing heart dam­age. Promis­ing, they said, but ap­par­ent­ly not promis­ing enough. Roche qui­et­ly dis­con­tin­ued that pro­gram af­ter Phase II tri­als and we didn’t hear about it again un­til to­day: Roche has sold it to a San Fran­cis­co biotech for a pal­try $2 mil­lion.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER